Company intelligence / Profile preview

Pinetree Health Technologies

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Pinetree Therapeutics has developed AbReptor™, a best-in-class multispecific antibody-based targeted protein degradation platform. Lead preclinical candidates target drug resistance mechanisms in oncology, including EGFR-mutated cancers. The company recently announced an exclusive option and global license agreement with AstraZeneca for its lead candidate. No clinical results yet reported as all programs remain preclinical as of mid 2025.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyProtein degrader
Industry: Biotech

Partnerships

AstraZeneca – exclusive option & global license agreement for lead AbReptor candidate targeting EGFR-mutant cancers.Massachusetts Life Sciences Center grant recipient.

Beyond the preview

Go deeper on Pinetree Health Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinetree Health Technologies.

Explore the full profile